Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Our current treatment paradigm of advanced anaplastic lymphoma kinase fusion (ALK+) non-small cell lung cancer (NSCLC) classifies the six currently approved ALK tyrosine kinase inhibitors (TKIs) into three generations. The 2nd-generation (2G) and 3rd-generation (3G) ALK TKIs are all “single mutant a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Nagasaka, Misako, Brazel, Danielle, Hou, Yujie, Zhu, Viola W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353359/
https://www.ncbi.nlm.nih.gov/pubmed/34365220
http://dx.doi.org/10.1016/j.tranon.2021.101191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353359/
https://www.ncbi.nlm.nih.gov/pubmed/34365220
http://dx.doi.org/10.1016/j.tranon.2021.101191

Ejemplares similares